D. Rosa

Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions

P. Pohlmann, A. Pohlmann, S. Garcia, 2022, Drug Safety.

Circulating Tumor DNA in HER2-Ampli fi ed Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

C. Sotiriou, S. Loi, M. Piccart, 2019 .

Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial

C. Sotiriou, S. Loi, M. Piccart, 2019 .

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial

C. Sotiriou, S. Loi, L. Pusztai, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer.

D. Larsimont, F. Cardoso, M. Piccart-Gebhart, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

C. Sotiriou, S. Loi, L. Pusztai, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

C. Sotiriou, S. Loi, M. Piccart, 2019, Clinical Cancer Research.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

R. Gelber, J. Baselga, Z. Aziz, 2021, European journal of cancer.

Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma

G. Jayson, P. Brenchley, R. Swindell, 2007, Cancer science.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

C. Sotiriou, S. Loi, L. Pusztai, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.